Intelligence · Clinical Development
Pipeline search results
Programs matching “qing” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.
Quick answer
Showing 138 pipeline programs matching "qing" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.
Refine search
Search results
-
PCN-101
Chongqing Precision Biotech Co., Ltd
Treatment Resistant Depression
1 trial -
PDI-192
Chongqing Precision Biotech Co., Ltd
Atopic Dermatitis
1 trial -
PDI-320
Chongqing Precision Biotech Co., Ltd
Rosacea
1 trial -
PRAX-114-231
Chongqing Precision Biotech Co., Ltd
Essential Tremor
1 trial -
PRAX-222 - Initial Dose
Chongqing Precision Biotech Co., Ltd
SCN2A-DEE
1 trial -
PRAX-628
Chongqing Precision Biotech Co., Ltd
Focal onset seizures or primary generalized tonic-clonic seizures
1 trial -
Part A: 20 and 40 mg PRAX-944
Chongqing Precision Biotech Co., Ltd
Essential Tremor
1 trial -
Qingying oral liquid and modified Da Huang-Huang Lian Xiexin mouthwash
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Radiation-induced Oral Mucositis
1 trial -
TQB3616 capsules
Chia Tai Tianqing Pharmaceutical Group Co.,
HR-positive, HER2-negative Advanced Breast Cancer
1 trial -
delolimogene mupadenorepvec
Chongqing Precision Biotech Co., Ltd
Malignant Melanoma
1 trial -
donor-derived NK cell infusion
Chongqing Precision Biotech Co., Ltd
Non-small Cell Lung Cancer
1 trial -
pCAR-19B cells
Chongqing Precision Biotech Co., Ltd
Acute Lymphoblastic Leukemia
2 trials -
Anti-CD123 CAR NK cells
Chongqing Precision Biotech Co., Ltd
AML (Acute Myeloid Leukemia)
1 trial -
Anti-CD19 UCAR-T cells
Chongqing Precision Biotech Co., Ltd
Dermatomyositis, Juvenile
1 trial -
Anti-CD5 CAR NK cells
Chongqing Precision Biotech Co., Ltd
T-ALL/Lymphoma
1 trial -
BCMA/CD70 CAR-T cells
Chongqing Precision Biotech Co., Ltd
Systemic Lupus Erythematosus
1 trial -
BCMA/CD70-targetd CAR-T
Chongqing Precision Biotech Co., Ltd
Juvenile Dermatomyositis (JDM)
1 trial -
BGM-2121
Chongqing Precision Biotech Co., Ltd
Advanced Solid Tumors
1 trial -
C-4-29 Cells
Chongqing Precision Biotech Co., Ltd
Multiple Myeloma in Relapse
1 trial -
CAR-T cells
Chongqing Precision Biotech Co., Ltd
Relapsed Non-Hodgkin Lymphoma
1 trial -
CD19 CAR-T cells
Chongqing Precision Biotech Co., Ltd
Systemic Lupus Erythematosus
1 trial -
CD19 targeted CAR-T cells
Chongqing Precision Biotech Co., Ltd
SLE (Systemic Lupus)
1 trial -
CD19-targetd CAR-T
Chongqing Precision Biotech Co., Ltd
Juvenile Dermatomyositis
1 trial -
CD70 CAR-T cells
Chongqing Precision Biotech Co., Ltd
Renal Cell Carcinoma
1 trial
Frequently asked questions
What is the Clinical Development Intelligence Platform?
It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.
How does this compare to Evaluate Pharma or Citeline?
Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.
Where does pipeline data come from?
Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.
Can I follow a company or program for updates?
Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.